The 7 most recent market catalysts affecting $EDIT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 85
Editas Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Editas Medicine announced its third-quarter 2026 financial results, showing a reduced net loss and increased revenue year-over-year. More significantly, the company presented compe…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Wells Fargo analyst Yanan Zhu upgraded Editas Medicine (EDIT) from Equal-Weight to Overweight and raised the price target from $4 to $6. This upgrade reflects a more optimistic out…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 75
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
Editas Medicine announced that its Phase 1/2 Strive clinical trial for EDIT-401 has received approval in Australia and is under review in New Zealand. This is a crucial development…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
The filing reports multiple analyst upgrades across different companies. For Editas Medicine (EDIT), Guggenheim upgraded the stock from Neutral to Buy with a $5 price target, a sig…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (EDIT) from Neutral to Buy and established a $5 price target. This upgrade signals increased confidence from a prom…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
Editas Medicine filed a mixed shelf offering prospectus, which is a standard regulatory step allowing a company to issue various types of securities (like common stock, preferred s…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
Editas Medicine (EDIT) announced Q2 earnings per share of $(0.15), significantly beating the analyst estimate of $(0.27), and sales of $11.900 million, far exceeding the $2.800 mil…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.